S. 1566 · 114th Congress
Cancer Drug Coverage Parity Act of 2015
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
KirkSponsor21 cosponsors · 15 D, 6 R
D
Franken
DV
R
Vitter
SC
R
Collins
BC
R
Cassidy
CM
D
Murphy
JM
D
Merkley
KG
D
Gillibrand
SB
D
Brown
MB
D
Bennet
TB
D
Baldwin
BM
D
Mikulski
LM
R
Murkowski
RW
R
Wicker
CC
D
Coons
CS
D
Schumer
AK
D
Klobuchar
SW
D
Whitehouse
EM
D
Markey
RB
D
Blumenthal
TC
R
Cochran
EW
D
Warren1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill amends the Public Health Service Act to require a group or individual health plan that covers anticancer medications administered by a health care provider to provide no less favorable coverage for anticancer medications administered by a patient.
What it does: CRS summary · Introduced in Senate · Jun 11, 2015
Cancer Drug Coverage Parity Act of 2015
This bill amends the Public Health Service Act to require a group or individual health plan that covers anticancer medications administered by a health care provider to provide no less favorable coverage for anticancer medications administered by a patient. A plan may apply to patient-administered anticancer medications only the cost-sharing and limitations that apply to anticancer medications administered by a health care provider.
These requirements apply to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with these requirements, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Cancer Drug Coverage Parity Act of 2015
Latest action (Jun 11, 2015): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Jun 11, 2015
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.